What are the most valued startups in the AI in drug discovery market?

Last updated: 13 March 2026

Download our beautiful pitch about the AI in drug discovery market

market research pitch 2026 statistics AI in drug discovery market

In our AI in drug discovery market deck, you will find everything you need to understand the market

The AI in drug discovery market has become one of the most active investment areas in biotech, with dozens of well-funded startups racing to compress the timeline from target identification to clinical candidate. We update this ranking every month so the data stays current and useful.

Some of these companies are already public, others have disclosed their valuations through funding announcements, and many are estimated using comparable company analysis and available financial signals. Every entry comes with a confidence level so you know exactly how much to rely on each figure.

The valuations here range from under $10M for early-stage platforms to over $5B for the most advanced AI-driven drug discovery companies, and the spread between them tells an interesting story about where the market is placing its bets.

And if you want to better understand this new industry, you can download our pitch covering the AI in drug discovery market.

A quick summary table

Create a small summary table using the CSS class table-summary, with two columns: Metric (in bold) and Value. Include the following rows: Most valuable AI drug discovery startup, Second most valuable AI drug discovery startup, Median valuation across the drug discovery AI landscape, Share of total drug discovery AI valuation captured by the top 10, Top startup valuation vs. median valuation, Median valuation-to-capital-raised ratio across drug discovery platforms, Drug discovery AI startups valued at $1B+.
Metric Value
Most valuable AI drug discovery startup XtalPi ($5.4B–$5.7B)
Second most valuable AI drug discovery startup Xaira Therapeutics ($5.0B–$6.5B)
Median valuation across the drug discovery AI landscape ~$220M–$320M
Share of total drug discovery AI valuation captured by the top 10 ~65%
Top startup valuation vs. median valuation ~20x
Median valuation-to-capital-raised ratio across drug discovery platforms ~1.5x–2.5x
Drug discovery AI startups valued at $1B+ 14
market map chart top companies startups AI in drug discovery market

In our AI in drug discovery market deck, we will give you useful market maps and grids

Top startups in the AI in drug discovery market ranked by valuation

Here is an updated table that ranks the top startups in the AI in drug discovery market based on their latest reported or estimated valuations.

If you want more detail about their fundraising activity, you can check our list of the startups who have raised the most funding in the AI in drug discovery market.

# Startup Name What They Do Current Valuation ($) Valuation Confidence Level Valuation Type Evidence Status Total Funding ($) Funding Confidence Level
1 Xaira Therapeutics AI drug discovery platform $5.0B–$6.5B Partial Confidence Implied Valuation from Raise Implied $1.0B Full Confidence
2 XtalPi AI plus robotics for R&D $5.4B–$5.7B Strong Confidence Public Market Cap Observed $1.5B Partial Confidence
3 Isomorphic Labs AI-first drug design company $4.8B–$6.2B Partial Confidence Implied Valuation from Raise Implied $600M Partial Confidence
4 Insilico Medicine AI-driven drug discovery platform $4.1B Full Confidence Public Market Cap Observed $806M Partial Confidence
5 Parabilis Medicines Helical peptide cancer drugs $2.6B–$3.2B Strong Confidence Implied Valuation from Raise Implied $812M Strong Confidence
6 insitro Causal biology AI drug discovery $1.8B–$2.6B Partial Confidence Comparables-Based Estimate Estimated $643M Full Confidence
7 Recursion Pharmaceuticals AI-native techbio drug discovery $2.1B Full Confidence Public Market Cap Observed $1.3B Strong Confidence
8 Soley Therapeutics Cell-stress oncology discovery platform $1.5B–$2.1B Strong Confidence Implied Valuation from Raise Implied $220M Partial Confidence
9 Odyssey Therapeutics Immunology and oncology medicines $1.5B–$1.9B Strong Confidence Implied Valuation from Raise Implied $700M Full Confidence
10 Genesis Therapeutics Generative AI small-molecule discovery $1.4B–$2.0B Partial Confidence Implied Valuation from Raise Implied $280M Strong Confidence
11 Generate:Biomedicines Generative biology protein therapeutics $1.6B Full Confidence Public Market Cap Observed $1.1B Full Confidence
12 Pathos AI AI oncology drug development $1.6B Strong Confidence Announced Private Round Valuation Observed $467M Strong Confidence
13 AbCellera AI antibody drug discovery $1.5B Full Confidence Public Market Cap Observed $671M Strong Confidence
14 Chai Discovery AI molecular design platform $1.3B Strong Confidence Announced Private Round Valuation Observed $230M Strong Confidence
15 Valo Health AI platform for therapeutics $1.0B–$1.5B Partial Confidence Comparables-Based Estimate Estimated $300M Low Confidence
16 Maze Therapeutics Genetics-driven precision medicines $1.2B Full Confidence Public Market Cap Observed $749M Strong Confidence
17 Owkin Multimodal AI for biology $1.0B–$1.3B Partial Confidence Comparables-Based Estimate Estimated $236M Partial Confidence
18 Enveda Biosciences Natural products drug discovery AI $1.0B–$1.2B Strong Confidence Announced Private Round Valuation Observed $525M Partial Confidence
19 Immunai Immune maps for therapeutics $900M–$1.1B Partial Confidence Comparables-Based Estimate Estimated $295M Strong Confidence
20 Relay Therapeutics Precision oncology drug discovery $900M Full Confidence Public Market Cap Observed $1.3B Full Confidence
21 Superluminal Medicines GPCR-focused AI small molecules $700M–$900M Strong Confidence Implied Valuation from Raise Implied $153M Strong Confidence
22 Terray Therapeutics AI small-molecule discovery engine $700M–$900M Partial Confidence Implied Valuation from Raise Implied $200M Strong Confidence
23 Eikon Therapeutics Live-cell imaging drug discovery $740M–$760M Strong Confidence Public Market Cap Observed $1.5B Full Confidence
24 EvolutionaryScale Protein-generating biology foundation models $650M–$850M Partial Confidence Implied Valuation from Raise Implied $142M Full Confidence
25 Exscientia AI-designed small-molecule medicines $688M Full Confidence Acquisition Value Observed $879M Strong Confidence
26 Cellarity Cell-behavior drug discovery $500M–$750M Partial Confidence Comparables-Based Estimate Estimated $294M Full Confidence
27 Relation Therapeutics Lab-in-loop target discovery $500M–$700M Partial Confidence Revenue or ARR Multiple Estimate Estimated $101M Partial Confidence
28 Iambic Therapeutics AI-native therapeutics discovery $550M–$650M Strong Confidence Implied Valuation from Raise Implied $303M Strong Confidence
29 Juvenescence AI-enabled longevity therapeutics $550M–$650M Strong Confidence Announced Private Round Valuation Observed $238M Partial Confidence
30 Cradle AI protein engineering platform $450M–$550M Strong Confidence Implied Valuation from Raise Implied $102M Full Confidence
31 Absci AI-designed biologic therapeutics $455M Full Confidence Public Market Cap Observed $503M Partial Confidence
32 METiS Therapeutics AI drug delivery platform $430M–$650M Partial Confidence Implied Valuation from Raise Implied $308M Partial Confidence
33 Inceptive AI RNA design platform $400M–$600M Partial Confidence Implied Valuation from Raise Implied $120M Strong Confidence
34 HAYA Therapeutics RNA-guided regulatory genome medicines $360M–$460M Strong Confidence Implied Valuation from Raise Implied $90M Strong Confidence
35 Proxima AI for proximity therapeutics $360M–$450M Strong Confidence Implied Valuation from Raise Implied $80M Full Confidence
36 Plexium Targeted protein degradation drugs $300M–$450M Partial Confidence Implied Valuation from Raise Implied $225M Partial Confidence
37 BioMap Life-science foundation model platform $350M–$500M Partial Confidence Comparables-Based Estimate Estimated $100M Partial Confidence
38 Deep Genomics RNA-focused AI drug discovery $300M–$500M Partial Confidence Comparables-Based Estimate Estimated $237M Strong Confidence
39 Ensem Therapeutics Oncology precision small molecules $320M–$480M Partial Confidence Comparables-Based Estimate Estimated $67M Strong Confidence
40 Medra Autonomous AI scientists for labs $300M–$380M Strong Confidence Implied Valuation from Raise Implied $63M Partial Confidence
41 BigHat Biosciences AI-designed therapeutic antibodies $290M–$330M Strong Confidence Announced Private Round Valuation Observed $99M Strong Confidence
42 HeliXon AI protein therapeutics discovery $280M–$420M Partial Confidence Comparables-Based Estimate Estimated $75M Strong Confidence
43 LabGenius ML antibody discovery platform $270M–$340M Partial Confidence Implied Valuation from Raise Implied $73M Strong Confidence
44 Healx Rare-disease AI therapeutics $250M–$380M Partial Confidence Revenue or ARR Multiple Estimate Estimated $115M Strong Confidence
45 Auron Therapeutics Cell-state oncology therapeutics $240M–$320M Strong Confidence Implied Valuation from Raise Implied $88M Full Confidence
46 Bioptimus Foundation models for biology $240M–$320M Partial Confidence Implied Valuation from Raise Implied $76M Full Confidence
47 Verge Genomics AI genomics drug discovery $220M–$360M Partial Confidence Comparables-Based Estimate Estimated $134M Full Confidence
48 Latent Labs Generative protein design platform $220M–$300M Partial Confidence Implied Valuation from Raise Implied $50M Strong Confidence
49 Aqemia Physics-first AI drug discovery $220M–$330M Partial Confidence Implied Valuation from Raise Implied $111M Partial Confidence
50 Atomwise AI small-molecule drug discovery $220M–$320M Partial Confidence Comparables-Based Estimate Estimated $219M Partial Confidence
51 Rezo Therapeutics Disease-network precision therapeutics $190M–$260M Partial Confidence Comparables-Based Estimate Estimated $78M Full Confidence
52 BioAge Labs Aging biology therapeutics $211M Full Confidence Public Market Cap Observed $647M Strong Confidence
53 Turbine Virtual biology disease simulations $190M–$280M Strong Confidence Implied Valuation from Raise Implied $61M Strong Confidence
54 PostEra AI medicinal chemistry platform $180M–$260M Partial Confidence Comparables-Based Estimate Estimated $27M Strong Confidence
55 CytoReason Computational disease models for pharma $180M–$240M Partial Confidence Comparables-Based Estimate Estimated $130M Partial Confidence
56 HotSpot Therapeutics Allosteric small-molecule drug discovery $180M–$260M Partial Confidence Comparables-Based Estimate Estimated $210M Full Confidence
57 ReviR Therapeutics RNA-targeting neurogenetic medicines $170M–$250M Strong Confidence Implied Valuation from Raise Implied $54M Strong Confidence
58 Tandem AI AI plus wet-lab discovery $150M–$220M Strong Confidence Implied Valuation from Raise Implied $82M Full Confidence
59 Quris-AI Bio-AI clinical prediction platform $150M–$220M Strong Confidence Implied Valuation from Raise Implied $37M Strong Confidence
60 Peptone Intrinsically disordered protein therapeutics $140M–$210M Partial Confidence Comparables-Based Estimate Estimated $43M Full Confidence
61 Converge Bio Generative AI drug discovery $140M–$190M Strong Confidence Implied Valuation from Raise Implied $31M Full Confidence
62 e-therapeutics RNAi drug discovery platform $130M–$170M Partial Confidence Implied Valuation from Raise Implied $128M Partial Confidence
63 Envisagenics RNA splicing therapeutics AI $130M–$180M Partial Confidence Implied Valuation from Raise Implied $47M Partial Confidence
64 Inductive Bio ADMET AI for optimization $130M–$180M Strong Confidence Implied Valuation from Raise Implied $29M Full Confidence
65 1910 Genetics Multimodal AI drug discovery $120M–$180M Partial Confidence Comparables-Based Estimate Estimated $26M Strong Confidence
66 Manas AI AI-native cancer drug discovery $120M–$170M Strong Confidence Implied Valuation from Raise Implied $51M Full Confidence
67 Standigm AI workflow drug discovery $120M–$220M Low Confidence Proxy-Based Estimate Estimated $70M Strong Confidence
68 Apeiron Therapeutics AI-guided precision oncology drugs $110M–$160M Partial Confidence Comparables-Based Estimate Estimated $45M Strong Confidence
69 BenevolentAI AI-enabled drug discovery platform $100M–$130M Low Confidence Proxy-Based Estimate Estimated $535M Low Confidence
70 Atomic AI RNA structure drug discovery $100M–$160M Low Confidence Implied Valuation from Raise Estimated $42M Full Confidence
71 Aitia Causal AI drug discovery $90M–$130M Partial Confidence Comparables-Based Estimate Estimated $66M Partial Confidence
72 Iktos Generative chemistry drug design $90M–$140M Partial Confidence Comparables-Based Estimate Estimated $16M Full Confidence
73 ImmunoPrecise Antibodies AI antibody discovery services $87M Full Confidence Public Market Cap Observed $22M Low Confidence
74 Anagenex Directed-evolution small-molecule discovery $70M–$100M Partial Confidence Implied Valuation from Raise Implied $37M Full Confidence
75 A-Alpha Bio Protein interaction discovery platform $70M–$110M Partial Confidence Comparables-Based Estimate Estimated $45M Full Confidence
76 Antiverse AI antibody discovery platform $50M–$80M Strong Confidence Implied Valuation from Raise Implied $17M Full Confidence
77 DeepLife Digital twins of cells $60M–$90M Partial Confidence Implied Valuation from Raise Implied $16M Partial Confidence
78 Partex AI-powered drug asset platform $50M–$80M Low Confidence Proxy-Based Estimate Estimated N/A N/A
79 Gero Aging-target discovery biotech $45M–$70M Partial Confidence Comparables-Based Estimate Estimated $8M Full Confidence
80 Valence Labs Generative chemistry AI engine $48M Full Confidence Acquisition Value Observed $9M Strong Confidence
81 Lantern Pharma AI-guided precision oncology $47M Full Confidence Public Market Cap Observed $101M Strong Confidence
82 PrecisionLife Precision medicine for chronic disease $40M–$65M Low Confidence Comparables-Based Estimate Estimated $11M Low Confidence
83 Cyclica Polypharmacology AI drug discovery $40M Full Confidence Acquisition Value Observed $21M Partial Confidence
84 Cyrus Biotechnology Computational protein design platform $30M–$50M Low Confidence Comparables-Based Estimate Estimated $32M Low Confidence
85 BlackThorn Therapeutics Neuropsychiatric drug development $37M Partial Confidence Acquisition Value Observed $130M Strong Confidence
86 BioXcel Therapeutics AI-enabled neuroscience therapeutics $37M Full Confidence Public Market Cap Observed $462M Partial Confidence
87 Evaxion Biotech AI-immunology vaccine developer $32M Full Confidence Public Market Cap Observed $65M Strong Confidence
88 Ignota Labs Rescuing failed drugs with AI $30M–$45M Partial Confidence Implied Valuation from Raise Implied $7M Full Confidence
89 Evariste Synthetic-lethal oncology discovery $28M–$38M Partial Confidence Comparables-Based Estimate Estimated $4M Partial Confidence
90 InveniAI AI target discovery platform $15M–$30M Low Confidence Proxy-Based Estimate Estimated $3M Low Confidence
91 Collaborations Pharmaceuticals AI drug discovery services $10M–$20M Low Confidence Proxy-Based Estimate Estimated Undisclosed Low Confidence
92 Reverie Labs AI molecular modeling software $10M–$20M Low Confidence Proxy-Based Estimate Estimated $32M Strong Confidence
93 DenovAI De novo protein design $12M–$20M Partial Confidence Proxy-Based Estimate Estimated $3M Partial Confidence
94 Oxford Drug Design AI-guided antibiotics discovery $12M–$20M Low Confidence Proxy-Based Estimate Estimated $8M Partial Confidence
95 BioSymetrics Phenomics-driven precision medicine AI $12M Full Confidence Acquisition Value Observed $5M Partial Confidence
96 oneThree Biotech Biology-driven drug toxicity AI $9M–$16M Low Confidence Proxy-Based Estimate Estimated $3M Strong Confidence
97 Cloud Pharmaceuticals Generative AI drug design $8M–$14M Low Confidence Proxy-Based Estimate Estimated $2M Low Confidence
98 Moleculern Wet-lab-driven AI drug discovery $8M–$15M Low Confidence Proxy-Based Estimate Estimated $0 Low Confidence
99 Predictive Oncology AI oncology, now compute pivot $6M Full Confidence Public Market Cap Observed $400M Low Confidence
chart market size 2026 AI in drug discovery market

In our AI in drug discovery market deck, we provide the data and the context to understand it

Key valuation trends in the AI in drug discovery market

Insights

  • Chai Discovery reached a $1.3B valuation on just $230M raised across three rounds completed in 15 months, making it one of the fastest seed-to-unicorn trajectories in AI drug discovery and a strong signal that molecular design platforms with credible technical differentiation can command premium valuations very early.
  • Parabilis Medicines closed a $305M Series F in January 2026 at an implied valuation near $2.9B, which represents roughly 3.5x the total capital raised, suggesting that late-stage oncology peptide platforms with clinical traction attract a meaningful valuation premium over earlier-stage AI drug discovery companies.
  • Eikon Therapeutics raised $1.5B in private capital but currently trades at roughly $750M in public market cap, making it the most capital-inefficient publicly listed AI drug discovery company and a reminder that strong private funding rounds do not guarantee strong public market reception.
  • Superluminal Medicines raised a single $120M Series A and carries an implied valuation of $700M–$900M, yielding roughly 5–6x valuation-to-funding, one of the highest capital efficiency ratios in the dataset and an outlier even among focused GPCR-targeted AI drug discovery platforms.
  • Proxima raised $80M in a single seed round in January 2026 at an implied valuation of $360M–$450M, the largest seed financing in the dataset, illustrating how stealth-to-launch capitalizations in AI proximity therapeutics have grown substantially compared to prior cohorts.
  • Among the six acquired companies in this dataset, Exscientia was acquired at $688M and Valence Labs at $48M, a 14x spread that reflects very different levels of platform maturity and clinical pipeline depth at the time of acquisition in the AI small-molecule drug discovery space.
chart exscientia AI drug discovery market

In our AI in drug discovery market deck, we identify repeatable patterns you can use if you’re building in this market

A few words about our methodology

As you can see, we built a database that ranks startups in the AI in drug discovery market based on their current valuation.

Estimating startup valuations is not always straightforward. Many AI drug discovery companies do not publicly disclose their valuation, and the available information can vary widely depending on the company and its stage.

To build this ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed companies, or official acquisition prices.

When a startup is publicly listed, we use its current market capitalization as the reference valuation.

If a company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, or customer traction, combined with valuation multiples from comparable companies in the same market.

When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, or product traction.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by strong operating metrics and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because valuation data in the AI drug discovery space is not always fully public, each startup in the ranking is assigned a confidence level based on the reliability, recency, and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

This reflects how we conduct all our research, including the work behind our report covering the AI in drug discovery market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

market growth rate cagrAI in drug discovery market

In our AI in drug discovery market deck, we answer all the common questions from investors and entrepreneurs

Related blog posts

- The latest news in AI for drug discovery

- The latest funding news in AI for drug discovery

- The latest update in AI for drug discovery

- The evolution of funding activity in AI for drug discovery

- The main fundraising trends in AI for drug discovery

- How large is the AI in drug discovery market in reality?

- A complete list of business models in AI for drug discovery

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog